Neil Exter - May 25, 2021 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
Director
Signature
/s/ Neil Exter
Stock symbol
RVMD
Transactions as of
May 25, 2021
Transactions value $
$0
Form type
4
Date filed
5/27/2021, 05:43 PM
Next filing
Jun 7, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Sale $0 0 $0.00* 0 May 25, 2021 See footnotes F1, F2, F3
transaction RVMD Common Stock Sale $0 0 $0.00* 0 May 26, 2021 See footnotes F3, F4, F5
holding RVMD Common Stock 0 May 25, 2021 See footnotes F3, F6
holding RVMD Common Stock 0 May 25, 2021 See footnotes F4, F5
holding RVMD Common Stock 20K May 25, 2021 Direct
holding RVMD Common Stock 20K May 25, 2021 See footnotes F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 25, 2021, Third Rock Ventures II, L.P. ("TRV II") sold 135,000 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $30.85 to $31.25, inclusive, at a weighted average price per share of $30.93. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1).
F2 After the above transaction, TRV II owned 1,774,317 shares of Common Stock of the Issuer.
F3 The Reporting Person is a partner of each of Third Rock Ventures GP II, L.P., TRV GP III, L.P. and Third Rock Ventures GP IV, L.P. which is the general partner of each of TRV II, Third Rock Ventures III, L.P. ("TRV III") and Third Rock Ventures IV, L.P. ("TRV IV" and collectively with TRV II and TRV III, "the Funds"), respectively. The Reporting Person disclaims beneficial ownership over the shares held by the Funds, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.
F4 On May 26, 2021, TRV II sold 1,231,204 shares of Common Stock of the Issuer in multiple transactions at prices ranging from $30.50 to $31.14, inclusive, at a weighted average price per share of $30.53. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4).
F5 After the above transaction, TRV II owned 543,113 shares of Common Stock of the Issuer.
F6 TRV III directly holds 5,524,031 shares of Common Stock of the Issuer and TRV IV directly holds 1,419,900 shares of Common Stock of the Issuer.
F7 The shares are directly held in certain estate-planning trusts over which the Reporting Person may have voting and dispositive power. The Reporting Person disclaims beneficial ownership over the shares held by such trusts except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that he is the beneficial owner of such shares.